as per the attachment
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cian Healthcare's board has approved two key changes effective March 16, 2026. Mr. Rajesh Jain, previously a Non-Executive Director, has been redesignated as Managing Director for a 3-year term, subject to shareholder approval. He holds an M.Pharm degree, is pursuing a PhD, and brings over 20 years of experience across pharmaceuticals, manufacturing, retail and marketing. Separately, Ms. Simmi Soni has been appointed as an Additional Woman Non-Executive Director; she has 15+ years of experience in administration, logistics and export coordination in the food supplement and pharmaceutical sectors. Both appointments will be placed before shareholders at the next general meeting. Notably, Mr. Rajesh Jain is related to existing director Mr. Pradeep Kumar Jain, indicating family involvement at the leadership level.
The elevation of a long-standing family-connected director to Managing Director signals consolidation of promoter/family control at the top, which may be viewed positively by aligned shareholders but could raise governance concerns among minority investors. The new woman director brings operational and supply-chain expertise to the board, modestly strengthening diversity and oversight.